PCSK9 and metabolic syndrome: In the 2019 ESC/EAS Guidelines for the management of dyslipidemias (Mach et al., 2019), it is stated that for secondary prevention, patients at very high risk not achieving their goal on a maximum tolerated dose of statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.